Next-generation Chimeric Antigen Receptor (CAR) T Therapies for Blood Cancers
Overview
CAR T cell therapies, with seven FDA‑approved products, have reshaped treatment paradigms for end‑stage hematologic malignancies by enabling durable responses in otherwise refractory patients. Despite these advances, clinical outcomes remain suboptimal, underscoring the need for next‑generation strategies capable of achieving deeper and more durable disease eradication.
Commercialisation opportunities
Technology licensing agreement
Problem addressed
Primary resistance and post treatment relapse continue to limit the long term efficacy of existing CAR T products. Overcoming these biological barriers is essential to achieving deeper and more durable disease clearance.
Innovation
- Our inventions adopt synthetic biology and chemical approaches by coupling or inducing CAR T cells with homing receptors to improve their bone marrow accessibility.
Key impact
- Improved marrow homing enhances early immune–tumor engagement.
- Enabling deeper disease clearance and reducing relapse risk.
Award
- 16th IIFME, WIPO Award + Gold Medal with Congratulations of the Jury
Application
- Integration with existing and future CAR designs, enabling platform‑level versatility
The Chinese University of Hong Kong (CUHK)
Founded in 1963, The Chinese University of Hong Kong (CUHK) is a forward-looking comprehensive research university with a global vision and a mission to combine tradition with modernity, and to bring together China and the West. CUHK teachers and students hail from all around the world. Four Nobel laureates are associated with the university, and it is the only tertiary institution in Hong Kong with recipients of the Nobel Prize, Turing Award, Fields Medal and Veblen Prize sitting as faculty in residence. CUHK graduates are connected worldwide through an extensive alumni network. CUHK undertakes a wide range of research programmes in many subject areas, and strives to provide scope for all academic staff to undertake consultancy and collaborative projects with industry.
Enquiry
